Compare AUBN & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUBN | THAR |
|---|---|---|
| Founded | 1907 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.7M | 90.8M |
| IPO Year | 1995 | 2022 |
| Metric | AUBN | THAR |
|---|---|---|
| Price | $23.95 | $2.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.7K | ★ 558.3K |
| Earning Date | 01-30-2026 | 11-12-2025 |
| Dividend Yield | ★ 4.44% | N/A |
| EPS Growth | ★ 754.96 | N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $32,340,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.87 | ★ N/A |
| Revenue Growth | ★ 40.58 | N/A |
| 52 Week Low | $19.00 | $0.95 |
| 52 Week High | $29.00 | $9.08 |
| Indicator | AUBN | THAR |
|---|---|---|
| Relative Strength Index (RSI) | 39.78 | 52.79 |
| Support Level | $23.70 | $2.76 |
| Resistance Level | $25.50 | $3.09 |
| Average True Range (ATR) | 0.65 | 0.26 |
| MACD | -0.28 | 0.00 |
| Stochastic Oscillator | 14.17 | 34.38 |
Auburn National Bancorp Inc operates as a bank holding company, which offers checking, savings, transaction deposit accounts and certificates of deposit, and is an active residential mortgage lender in its primary service area. The Bank's primary service area includes the cities of Auburn and Opelika, Alabama and nearby surrounding areas in East Alabama, predominantly in Lee County. The Bank also offers commercial, financial, agricultural, real estate construction and consumer loan products and other financial services. The Bank also provides automated teller machine (ATM) services in East Alabama and operates ATM machines. The Bank offers Visa Checkcards, which are debit cards. The Bank offers online banking, bill payment and other electronic banking services through its Internet website.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.